Powell, Jerry S <br/><br/>
Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients.  [electronic resource] 

 -  Blood  Mar 2012 
 - 3031-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1528-0020 
<br/><br/><label>Standard No.: </label>10.1182/blood-2011-09-382846  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Dose-Response Relationship, Drug<br/>Factor VIII--administration & dosage<br/>Half-Life<br/>Hemophilia A--blood<br/>Humans<br/>Immunoglobulin Fc Fragments--administration & dosage<br/>Infusion Pumps<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Receptors, Fc--administration & dosage<br/>Recombinant Fusion Proteins--administration & dosage<br/>Time Factors<br/>Young Adult<br/>von Willebrand Factor--analysis